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Research at the population level has provided an exhaustive body of evidence on the viral etiology of cervical cancer, and on the human papillomavirus (HPV) types involved. Most of the progress made by epidemiological studies has been based on DNA technology to characterize the presence of the human papillomavirus DNA (HPV-DNA) in cervical specimens. Investigations have demonstrated that a range from 2% to more than 20% of the world's female population have detectable HPV-DNA in their cervix at any time. Further, it has been established that, under certain conditions, these infections persist and are able to induce CIN2/3 and cervical cancer. Currently, the viral DNA can be detected in virtually all cases of invasive cancer. High parity, smoking, and long-term use of oral contraceptives have been established as risk cofactors for cervical cancer among women with persistent infections with HPV. Other sexually transmitted diseases such as Chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus as well as some poorly known dietary factors are likely intervening factors.
Continued research should focus on producing better estimates of the burden of disease linked to papillomaviruses. In the future, cancer registries should play an important role by monitoring cervical cancer incidence in populations vaccinated against HPV. Additional investigations should further explore the natural history and the cofactors that modulate the risk of cancer among HPV infected women.
BURDEN OF HPV INFECTION, CERVICAL NEOPLASIA, AND CERVICAL CANCER
Definite progress in understanding the etiology of cervical cancer has been achieved, and some types of HPV have been established as the central cause of cervical cancer worldwide (1) . Further, technology is available to detect the presence of viral DNA in large volumes of cervical specimens, and a substantial number of epidemiological investigations are providing estimates on the prevalence and distribution of the HPV infections in human populations. Serological measurements of the typespecific antibody levels against HPV capsid antigens combined with DNA studies have provided evidence that most of the sexually active women (up to 70% in some populations in the United States) have been exposed to HPV at any point in time. Seroconversion following HPV exposure is, however, not universal; and with current detection methods, a range between 40 and 50% of HPV-DNA 16 positive cervical cancer cases do not show HPV16 antibodies. The natural history and the determinants of the immune response to HPV are still poorly understood, and antibody measurements have had limited use, thus far, in epidemiological studies. Table 1 (2-27) shows a selection of studies that investigated the prevalence of HPV-DNA in women from the general population in different regions in the world. Studies are included in the table for the following reasons: 1) they represent in as much as possible the underlying populations, although not necessarily of the country or the corresponding world's region; 2) they used polymerase chain reaction (PCR) or Hybrid Capture 2 (HC2) technology to assess the presence of the viral DNA; and 3) they include a wide age range, a study size of at least 200 individuals, and had a well described methodological section in their pub-lished account. The table shows two prevalence estimates, one for all women included in the study, and one for women ages 30 years and above. The latter is generally considered an approximation of the prevalence of persistent carriers. This interpretation recognizes that most HPV infections are acquired soon after sexual initiation and are also cleared at an early age. Women who are HPV-DNA positive at ages 30 and above (allowing for certain intercountry variation) may represent failure of viral clearance and select the group of women at a relative higher risk of cervical cancer.
Prevalence of HPV-DNA in Cervical Specimens from the General Population
The results displayed in Table 1 should be viewed as an approximation to the burden of the viral infection estimated by the HPV-DNA detection rate in cervical scrapes at a point in time. Limitations to current data include the variability introduced by the selection of the population, the sampling methods, and by the variability of the techniques used for HPV detection, specifically when nonstandardized PCR methods are used locally. In countries with intensive screening among young women, aggressive treatments of early or ambiguous cytology lesions (most of which are likely to be HPV-related) may have resulted in a reduction of the estimated HPV-DNA prevalence in more advanced age groups. In a few epidemiological studies, the exact same methods in the field and in centralized laboratories have been used to investigate populations of contrasting incidence of cervical cancer (i.e., Colombia and Spain, North and South Vietnam, International Agency for Research on Cancer (IARC's) multicentric case control studies, different surveys in the United Kingdom). These studies have consistently shown strong geographical correlations between HPV-DNA prevalence and cervical cancer incidence. 
HPV Prevalence in Cervical Cancer Cases and HPV-type Distribution in Cases and Controls
State-of-the art amplification techniques used in clinical and epidemiological studies have shown unequivocally that in adequate specimens of cervical cancer, HPV-DNA can be detected in 90% to 100% of the cases in any population where investigations have taken place. This compares with a prevalence of 5% to 20% from cervical specimens of women without cervical cancer, from the same populations (i.e., prevalence surveys or control groups in case control studies). Detailed investigations of the few cervical cancer specimens that appear as HPV-DNA negatives on routine testing strongly suggest that these are largely false negatives (28, 29) . As a consequence, the claim has been made that this is the first necessary cause of a human cancer ever identified, and it provides a strong rationale for the use of HPV tests in screening programs and for the development of HPV vaccines.
Of the more than 35 HPV types found in the genital tract, HPV16 accounts for 50% to 60% of the cervical cancer cases in most countries, followed by HPV18 (10%-12%) and HPVs 31 and 45 (4%-5% each). Fig. 1 shows the cumulative distribution of the most common types in close to 5000 specimens included in the IARC's multicenter cervical cancer studies. Among cases, HPVs 16, 18, 45, 31, and 33 accounted for 80% of the type distribution in squamous cell carcinomas and HPVs 16, 18, 45, 59, and 33 accounted for 94% of the type distribution in adenocarcinomas. To complete the additional 6% to 20%, the required number of HPV types increases to 20-23 types, each one of which would contribute between 3% and 0.1% of the types. These results should be viewed as indicative, because some of the testing systems used may be relatively less sensitive to the rarer types, notably in the presence of multiple infections in the same specimen. In most studies, HPV18 predominates in adenocarcinomas in absolute or in relative terms, however, the reasons for such specificity are still unknown. In the same studies, HPVs 16, 18, 45, 31, and 33 accounted for 46% of the prevalence observed in HPV-DNA positive women with normal cervical smears.
These distributions are generally consistent worldwide (28, 30) , although several reports using highly sensitive HPV-DNA detection and typing systems are finding additional geographical variability (2, (31) (32) (33) , and for several regions in the world the information is either lacking or rather scarce.
Discussion points/recommendations are as follows: 1) It would be important to have updates of the international literature on the prevalence and type distribution of HPV-DNA in the general population and in cervical cancer cases. These estimates should consider the various parameters that affect detection, notably the testing system and the biological specimens used. Such reviews may have implications for HPV vaccine composition.
2) It would be desirable to conduct additional surveys designed to cover the gaps in the maps, notably by including selected areas in Africa and Asia and in populations heavily exposed to the human immunodeficiency virus (HIV), malnutrition, and malaria. Assessment of the prevalence of viral variants of the most common types remains to be done. Methodological exercises have to be conducted to determine the proper HPV-DNA typing methods to be used, particularly if multiple vital types are common.
3) It is still worth replicating the findings of investigations on putative HPV-negative cervical cancer cases using, for example, microdissection technology and in situ hybridization methods to confirm that the 5-15% HPV-negative cases that are currently being reported from field or clinical studies are generally false-negatives. Table 2 shows estimates of the incidence of invasive cervical cancer as extracted from systematic sources, and compiled by IARC for the years 1985, 1990, and 2000 (34-36) . The data included in the table have been calculated from incidence rates, mortality vital statistics, and census records. For some underinvestigated populations, other ancillary sources and country-tocountry extrapolations are occasionally used. Thus, the reliability of the figures in the table may differ by region. Table 2 shows the impact of the adjustment methods on the perception of risk by geographical regions. For example, crude rates are similar when the world is broadly divided into developing and developed regions; however, age-adjusted rates using the age structure of an artificial world standard population tend to decrease the estimates for developed (older) populations and to increase the estimates for less developed (younger) populations.
Incidence and Mortality of Cervical Cancer
Comparison of columns 2 to 4 ( Table 2) shows one of the limitations of current estimates. When estimates for 1985 and 2000 are related, there appears to be a slight reduction in the total number of cases in developed countries and an increase in developing regions, notably in Africa, The Caribbean, and Central and South America. Estimates for 1990 are lower, strongly driven by an inconsistent reduction in the estimates for the different regions in Asia. Some authors have also reported substantial reductions in the mortality from cervical cancer in China in the interval 1970-1994 (37) . However, artifacts due to differences in the diagnostic and registration methods cannot be excluded, notably when a few incidence registries are used to produce estimates for large populations.
From the same source, the number of cervical cancer deaths in the world has been estimated as 233 400, which is close to half of the incident cases. The 5-year prevalence of cervical cancer has been estimated at 1.4 million cases (36) . The estimated total number of cases of cervical cancer as presented in Table 2 is being largely accepted as a background reference. It is also often used for the promotion of preventive interventions in both developed and developing regions. However, to fully estimate the impact of cervical cancer, the limitations of current estimates have to be recognized and it is important to reach a comprehensive interpretation of the different parameters reflecting disease burden such as the four (number of cases, crude rates, age adjusted rates, and age-specific rates) presented in Table 2 .
In broad terms, it should be recognized that cervical cancer is a strong determinant of women's cancer incidence and mortality in developing countries and that current figures may still underestimate its impact due to under diagnosis and under registration. Developed countries that have introduced massive screening have successfully shifted the focus of attention toward preinvasive neoplasm. However, in large developed regions with unevenly implemented screening programs and an aging population, like in Europe, the total number of cases of cervical cancer diagnosed (some 65 000 cases) is still at a similar level as the one estimated for Africa (some 67 000 cases) and not far from the estimates for Central and South America combined (some 70 000 cases).
Discussion points/recommendations are as follows: Cancer registries should continue to monitor the incidence of cervical cancer and to allow the evaluation of preventive strategies implemented
Time Trends in Cervical Cancer Incidence by Histology
Individual cancer registries provide the information required to estimate time trends in incidence in their populations. In countries with organized screening, decreases in rates for cervical cancer have been reported consistently, whereas increases in the incidence of cervical adenocarcinomas have been reported in several populations (38) (39) (40) . Cervical adenocarcinomas currently represent 10% to 12% of cervical cancer and are an increasing concern of cytology-based screening programs. It is likely that these upward trends are the results of major changes in sexual behavior initiated in the 1950s and 1960s in their populations and to the failures of screening programs in the subsequent decades. It is known that cytology-based screening has a relatively lower sensitivity for the early glandular lesions than for the squamous-cell cancer precursors. Alternative explanations could consider the possibility that the underlying prevalence of the HPV types more related to cervical adenocarcinoma is changing over time (i.e., that the trends in prevalence of HPV18 are increasing). In addition, changes in the exposure of the populations to relevant cofactors should be considered.
Discussion point/recommendation follows: It would be of interest to verify if there are any underlying time trends in the type distribution of HPV in cervical cancer. Studies of decadesold archival cervical cells or tissues are warranted.
Age-Specific Incidence of Cervical Cancer
In most developed countries, cervical cancer incidence shows a unique profile across age groups in that rates increase sharply after ages 25-30 years to reach a plateau after ages 45-50 years. With the availability of results from cancer registries in developing countries, it has been possible to recognize that, in the absence of screening, cervical cancer tends to follow a linear relationship with age, which is the pattern of the majority of the epithelial tumors. The shape of the age-specific incidence curve seems to be highly dependent on the screening efforts. Fig. 2 A shows an example from the United Kingdom and Brazil (41) . Both countries show similar rates of invasive cervical cancer to age 30 years, suggesting similar levels of exposure to HPV, but rapidly separate apart in more advanced age groups, probably as a consequence of the organized screening program in the United Kingdom. The arithmetic scale has been chosen on this occasion for better visualization of differences. Figure 2 B (41) shows significant differences in the agespecific incidence rates in northern America across ethnic groups. Data on white populations from the Surveillance, Epidemiology and End Results Program (SEER 1 ) and Canadian registries show that incidence rises steeply between ages 20 and 35 and stays stable in the middle-aged groups, with some slight increase after age 55 years. In contrast, the incidence increases steadily throughout lifetime for Blacks, Hispanic, and Chinese (with an unexplained and short-lasting dip between age groups 65-75 years), reaching two to three times the incidence among whites in the most advanced age groups. Migrant populations from high-to low-risk countries may have an important impact on the incidence of cervical cancer, notably if they remain outside of the screening system.
In some countries, a second mode in the incidence of cervical cancer among women in the age groups over 55-60 years is observed. Fig. 2 C shows these distributions for some selected cancer registries in Europe. The interpretation of the second mode remains uncertain. Decrease in screening coverage or lower sensitivity of cytology in the old age groups are plausible explanations but immunosuppression or acquisition of new HPV infections during middle age cannot be ruled out. In the age groups 35 years and above, the presence of HPV-DNA in cervical cells probably reflects a combination of long-term persistent infections acquired in the younger age groups and newly acquired late infections. New infections should be largely related to changes in sexual behavior of both sexes. It can be hypothesized that, after a certain latency period, the presence of a recently acquired viral DNA in the middle-aged group, with or without the concurrent effect of cofactors, is capable of generating a second increase in the incidence of CIN3 and of invasive cancer (see also a discussion on the "Incidence of CIN3" section below). The predicted height of the second mode is modulated (attenuated) by both screening in these age groups and competing causes of death.
Discussion points/recommendations are as follows: 1) Cohort studies should continue to provide data on sexual behavior during middle age and above age groups, notably among males. 2) Analyses of cervical cancer incidence by birth cohorts in different populations should be encouraged. These could relate current incidence of cervical cancer to past populationadopted changes in sexual behavior and to major migrant changes.
Incidence of CIN3
There is limited information on the incidence of CIN3 lesions. However, in terms of burden of cervical pathology and the requirements imposed to the health systems in developed countries, it is likely that CIN3 is one of the key diagnoses to consider. Figure 3 shows estimates of the incidence of carcinoma in situ/CIN3 and of invasive cancer as provided by some registries. The figure shows very high rates of CIN3 in the young age groups (i.e., >400 per 100 000 in the 20 to 30 years old in the East Anglia Cancer Registry in the United Kingdom). Occasionally, a second mode in the 50 years and above age groups is observed. It is still uncertain which proportion of these CIN3 cases are deemed to progress to cervical cancer as compared with representing transient morphological changes. The population-based ratio of CIN3-to-invasive cancer seems a parameter of relevance that may provide indirect estimates of the amount of over diagnosis and overtreatment of pre-invasive lesions brought about by screening programs. For example, Fig. 3 A shows that in Finland, a country with a long-term, centralized, and well-established screening program, there are 1.6 cases of CIN3/in situ carcinoma per case of invasive cancer diagnosed. In contrast, the equivalent ratios for East Anglia and Iceland are 13.0 and 16.2, respectively ( Fig. 3 B and C) . It is uncertain if, in the absence of screening, all these CIN3/in situ cases would have progressed to invasive cancer. These observations may also reflect the variability in diagnosis and treatment of pre-invasive disease across populations.
Discussion points/recommendations are as follows: It would be of interest to stimulate additional work on the incidence of pre-invasive lesions, including additional collection of data on the incidence of CIN3/carcinoma in situ and analysis of the available data from cancer registries. These analyses could relate incidence to the age-specific prevalence of HPV-DNA and to the corresponding incidence of invasive cancer. Analysis of the ratios of CIN3/cervical cancer considering other clinical parameters (i.e., standardization of the CIN3 diagnosis and pathology results from conization specimens) may allow estimates of the fraction of the CIN3 cases that are true precursors of cervical cancer in the context of specific screening practices. Newly organized screening programs or screening trials in developing populations (i.e., for HPV testing or direct visual inspection methods) should be able to estimate ratios of CIN3 to invasive cervical cancer in populations in the absence of preventive interventions. Analysis of the age at occurrence of CIN3 and of the ages at sexual initiation may provide new insights into the latency period for HPV and cancer.
Modeling Geographic Variation in Cervical Cancer Incidence as a Basis for Classifying Populations in Relation to Their Risk of Cervical Cancer
Maps of cervical cancer incidence based on age-adjusted rates tend to indicate that countries at high-risk cluster in subSaharan Africa, Latin America, and some parts of Asia. Identification of key environmental factors that may modify the risk of HPV exposure and the incidence of cervical cancer offers new and attractive opportunities to generate models of cervical cancer incidence. These estimates would allow a fresh look at the classification of populations in relation to their risk independently of the strong impact of screening.
At a population level, high incidence rates of cervical cancer are observed and can be predicted for populations with high HPV-DNA background prevalence, paired with (and consequent to) an early age at sexual initiation, high number of partners of both men and women, and an important frequency of sexual contacts with prostitutes. Typically, these populations also have high parity and high frequency of exposure to other risk factors (e.g., oral contraceptives, smoking, other sexually transmitted diseases, poor hygiene, and cervical inflammation). Over and above their exposure levels, high-risk populations are dramatically underserved by screening programs or practices. On the reverse side, low-risk populations show either low levels of exposure to these factors and/or belong to communities with centralized and quality-controlled screening activity. As expected, countries and populations include unequal combinations of these risk and protection factors.
Developed countries share many high-risk traits, largely compensated by important screening efforts and decreasing parity. The ratio of incident cases of CIN3/invasive cervical cancer tends to be high (i.e., 10/1). Examples of such countries could be the United States or some of the Nordic countries in Europe.
Developing countries under strict religious (behavioral) influence show some low-risk traits (regulated sexual behavior, low prevalence of exposure to cofactors) and some high-risk traits such as high parity and absence of screening programs. These countries tend to show low incidence rates of cervical cancer, although the number of registries in these populations is also limited. Examples of this model would be the Muslim countries in the Middle East or Asia.
Other developing countries without strict religious (behavioral) regulations accumulate high-risk traits not compensated by screening efforts. These situations result in the highest incidence rates of invasive disease recorded. Examples of this could be some populations in Central and Latin America.
The combination of these factors into a model of disease incidence could be used to predict incidence of cervical cancer by birth cohorts when properly placed into populationspecific time scales. This information would provide the rationale for the continuous support and development of screening programs. The models could also be used to estimate indirectly the efficiency of screening programs in developed countries, by comparing the predicted and the observed incidence rates. An ecological project along these lines has recently reported a strong correlation between predominant religion and cervical cancer in developing countries (42) .
Discussion points/recommendations are as follows: The acquisition of novel data on HPV prevalence and its determinants in a variety of regions covered by cancer registries encourages systematic analysis leading to the construction of statistical models of cervical cancer incidence. Migrant studies and HPV variant distributions could be of value.
CAUSALITY ASSESSMENT: HPV AND OTHER RISK FACTORS FOR CERVICAL CANCER
The nature of the association between HPV and cervical cancer has been exhaustively investigated and since the early 1990s, and all academic reviews have consistently concluded that the evidence fulfills most of the established criteria of causality (1) . The mechanisms by which HPV induces cancer in humans and the molecular genetics of the process are being intensively investigated and excellent reviews are available (43) . To evaluate the role of additional factors once it was recognized that the role of HPV-DNA was a necessary factor it became a standard procedure to restrict the analysis to women who were HPV-DNA-positive (thus at risk of ever developing cervical cancer) in addition to the standard multivariate methods. Table  3 (1, [44] [45] [46] [47] [48] summarizes the established risk factors of cervical cancer in women who are carriers of HPV-DNA, and Table 4 (49) (50) (51) presents the factors that are significantly related to cervical cancer in HPV-DNA positive women, but for which conclusive evidence is less established. As before, most of the conclusions and references quoted are results of the IARC's multicenter study, which are consistent with the updated literature.
Current Risk Estimates for HPV-DNA and HPV Type-Specific Estimates
Current estimates of the odds ratio for HPV-DNA and cervical cancer are among the highest observed in human cancer. The final results of the IARC multicenter study reports an estimate of invasive cancer for HPV-DNA of OR ‫ס‬ 158 (95%CI ‫ס‬ 113.4 to 220.6) (44). Corresponding risk estimates for HPV16 was OR ‫ס‬ 434.5 (95% CI ‫ס‬ 278.2 to 678.7) and for HPV18 OR ‫ס‬ 248.1 (95%CI ‫ס‬ 138.1 to 445.8). The size of the project has allowed the generation of estimates of the associations between individual HPV types and cervical cancer. According to these results, any of at least 15 high-risk types, namely HPVs 16, 18, 45, 31, 52, 33, 58, 35, 59, 51, 56, 39, 68, 73 , and 82 (IS39 / W13B, MM4), convey a statistically similar risk of developing cervical cancer. HPVs 26, 53, and 66 probably are also high-risk types; however, the limited number of observations with these viral types precluded a firmer conclusion. Nonsignificant differences between point estimates may reflect the overwhelming predominance of some of the types (i.e., HPVs 16 and 18) over other types. This IARC study also confirmed the strong correspondence between the epidemiological risk classification of HPV types and the phylogenetic classification which is based on comparisons of DNA sequences across types (44) .
Relative risks generated by cohort studies with limited HPV observations and short-term follow-up tend to be smaller than odds ratios generated by case-control studies. These studies are informative of the putative pre-invasive stages (low-grade squamous intra-epithelial lesions [LSIL] and high-grade squamous intra-epithelial lesions [HSIL]) but are difficult to interpret in terms of causality of cervical cancer. This is due to censoring of the women at highest risk because of treatment. Moreover, if in fact a fraction of the CIN3 cases (and most importantly if HSIL is the diagnostic endpoint) are not true cancer precursors, misclassification of the diagnosis may partly explain the lower risk estimates in cohort studies. Long-term cohorts that can reliably establish persistency of the same viral types have clearly established the time sequence between HPV exposure and cervical neoplasia and tend to report risk estimates at the level of the case-control studies referred above.
It is plausible that novel DNA detection methods result in higher prevalence of HPV-DNA in women with normal cervical cytology. Some early work in Costa Rica using a different polymerases in the PCR reaction has resulted in an increased estimate of the HPV-DNA prevalence in controls (52) . If current underdetection is a general issue, future studies would generate lower risk estimates; however, it is unlikely that any significant 
STDs ‫ס‬ sexually transmitted diseases. (48) modification of the attributable fraction would occur as a result because of the direct relevance of the prevalence of HPV-DNA in cases in the calculations of the attributable fraction. In large prevalence surveys of HPV types in invasive cancer "low-risk HPV types" (e.g., HPV 6 or 11) are anecdotally found as the only type (44) . Some cohort studies have likewise described that HPV 6 or 11 are predictors of both LSIL and HSIL (53) (54) . Experimental studies have occasionally shown that the E6 and E7 genes of low-risk types are capable of interfering with p53 and Rb at a low efficiency level [reviewed in (43) ]. These results, although of little clinical relevance, are intriguing in that they indicate that, under certain circumstances, even low-risk types may be able to induce neoplastic changes and cancer.
The proportion of multiple types in a given cervical cancer specimen varies across studies and particularly in relation to the HPV detection method used. Populations at high-risk of cervical cancer and populations with high rates of HIV tend to show higher proportions of multiple types as compared wtih populations not belonging to these risk groups (55) . In the IARC multicenter study there was no statistically significant increased risk for women with multiple-type infections (OR ‫ס‬ 115.6; 95% CI ‫ס‬ 69.3 to 192.8) over women positive for only one HPV type (OR ‫ס‬ 172.5; 95% CI ‫ס‬ 122.2 to 243.6) (44). The finding is consistent in other settings (8) , giving support to the notion that each HPV infection acts independently. However, some underdetection of multiple types may have occurred as a consequence of the HPV detection systems used.
Research Issues on HPV and Cervical Cancer: Viral Factors
Viral factors under investigation include the study of HPV variants, the measurement of HPV viral load, and viral integration. Limited information is available on HPV16 variants, suggesting an increased risk for some of the non-European prototypes (56) . Viral load has been proposed as a useful marker in cohort studies with conflicting results (8, (57) (58) (59) . Part of the discrepancies can be related to the endpoints used in cohort studies (usually lower or equal to HSIL). Technology to characterize viral load has not been fully validated. Viral integration into cellular DNA was proposed as a marker of progression to cervical cancer. Integration is rarely seen in pre-invasive disease and invasive cancer shows either episomal or integrated viral DNA. It is still uncertain if integration in stages of HSIL predicts progression to cervical cancer.
Research Issues on HPV and Cervical Cancer: Host Factors
The host response and, possibly, genetically determined susceptibility remain the less understood of the key variables in the carcinogenic process. For example, experimental studies reporting an increase in risk among carriers of certain polymorphisms suggested that there is a susceptibility factor to HPV in p53 (60) . However, these results were only occasionally confirmed by epidemiological data (61). Little has been done in trying to describe familial aggregation of cervical cancer, notably to disentangle the effects of an inherited trait from the effects of shared environment, behavior, and attitudes. One such attempt attributed one-third of the variance in cervical cancer incidence to shared genetic makeup.
Discussion points/recommendations are as follows: It is uncertain if we need additional case control studies to investigate the basic HPV association with cervical cancer. New studies should focus on the exploration of additional associations with putative environmental cofactors (e.g., dietary factors) among HPV-DNA positive women, novel viral markers, and markers of viral and host interactions. Epidemiologists would benefit from storing biological materials from studies to be able to test novel hypothesis in well-characterized study populations. Amongst others, it would be desirable to see studies that would include the following: 1) Research into mechanisms of HPV carcinogenesis. Explore in greater detail the occasions in which low-risk HPV types are capable of inducing neoplastic transformation. 2) Consider issues of specificity of viral types (and of variants) to induce either squamous cell or adenocarcinoma in the cervix and of type specific biological advantages that could explain the predominance of HPV16 and to some extent of HPV18 over all other mucosal HPV types. 3) Generate more data on multiple types by determining the viral type implicated in a cancer in which several types are identified (i.e., by microdissecting the tissue and/or with carefully conducted in situ hybridizations) 4) Provide additional data on the risk linked to HPV variants. It would be necessary to develop technology that allows typing and variant detection in large numbers and generate worldwide results in the same manner as it has been done for the HPV type distributions. 5) Standardize technology for measuring viral load and viral integration in routine cohort studies. 6) Characterize new biomarkers of interaction between HPV-DNA and cellular DNA that would signal latency, persistency, or progression to neoplasm. 7) Characterize biomarkers of genetic susceptibility to be used in population studies and pursue research into the familial aggregation of cervical cancer. 
NOTES 1
Editor's note: SEER is a set of geographically defined, population-based, central cancer registries in the United States, operated by local nonprofit organizations under contract to the National Cancer Institute (NCI). Registry data are submitted electronically without personal identifiers to the NCI on a biannual basis, and the NCI makes the data available to the public for scientific research.
